Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$12.41 USD
+0.72 (6.16%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.40 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STOK 12.41 +0.72(6.16%)
Will STOK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STOK
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
Other News for STOK
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer
Buy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioning
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Haleon PLC (GB:HLN) and Stoke Therapeutics (STOK)
12 Health Care Stocks Moving In Friday's After-Market Session